IPC The Hospitalist (Nasdaq: IPCM) reported earnings on Oct. 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), IPC The Hospitalist missed slightly on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share grew significantly.

Margins expanded across the board.

Revenue details
 IPC The Hospitalist tallied revenue of $127.7 million. The 11 analysts polled by S&P Capital IQ anticipated net sales of $130.1 million on the same basis. GAAP reported sales were 12% higher than the prior-year quarter's $114.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.46. The 12 earnings estimates compiled by S&P Capital IQ predicted $0.49 per share. GAAP EPS of $0.46 for Q3 were 21% higher than the prior-year quarter's $0.38 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 26.7%, 90 basis points better than the prior-year quarter. Operating margin was 9.7%, 40 basis points better than the prior-year quarter. Net margin was 6.1%, 50 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $135.0 million. On the bottom line, the average EPS estimate is $0.48.

Next year's average estimate for revenue is $521.9 million. The average EPS estimate is $1.90.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 71 members out of 77 rating the stock outperform, and six members rating it underperform. Among 18 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give IPC The Hospitalist a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on IPC The Hospitalist is hold, with an average price target of $43.80.